Clinical Trials Logo

Humoral Rejection clinical trials

View clinical trials related to Humoral Rejection.

Filter by:
  • None
  • Page 1

NCT ID: NCT05890430 Not yet recruiting - Clinical trials for Kidney Transplantation

Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation

RECITE
Start date: June 2023
Phase:
Study type: Observational

We will study a prospective cohort including all kidney transplant recipients undergoing kidney graft biopsy in one kidney transplantation center, for a duration of 5 years. Our primary outcome is to compare the number of circulating NK cells between patients and without humoral rejection. Our secondary outcomes are to describe the cellular, genetic, humoral, and histological characteristics of humoral rejection and their evolution.

NCT ID: NCT03801135 Recruiting - Clinical trials for Guillain-Barre Syndrome

Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation

Start date: October 3, 2018
Phase: N/A
Study type: Interventional

Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels. The aim of study is to define coagulation status of patient after plasmapheresis with different laboratory tests and to investigate the possibility of fibrinogen concentrate replacement for the correction of induced coagulation disorder.

NCT ID: NCT01895127 Terminated - Clinical trials for Antibody-mediated Rejection

Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.